GT Biopharma Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells October 22, 2019
GT Biopharma Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells October 3, 2019
GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics September 24, 2019
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial September 12, 2019
